Gain Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended September 30 · · Nine Months Ended September 30 | ||||||||||||
| · · 2026 · · 2025 · · 2026 · · 2025 | ||||||||||||
| Net loss | | $(3,160,408) | | $(5,284,373) | | $(13,444,711) | | $(15,623,518) | ||||
| Components of other comprehensive income (loss): | | | | | | | | | | | | |
| Changes in defined benefit pension plan obligation, net of tax | | | (4,305) | | | 5,308 | | | 56,280 | | | 16,068 |
| Foreign currency translation | | (126,800) | | (26,170) | | 39,498 | | 794,702 | ||||
| Other comprehensive income, net of tax | | | (131,105) | | | (20,862) | | | 95,778 | | | 810,770 |
| Comprehensive loss | | $(3,291,513) | | $(5,305,235) | | $(13,348,933) | | $(14,812,748) | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.